Xinbang Pharmaceutical released its 2024 annual performance, with a net profit attributable to the parent company of 101 million yuan, a year-on-year decrease of 64.70%

Xinbang Pharmaceutical released its 2024 annual report, with operating revenue of 6.032 billion yuan, a year-on-year decrease of 6.63%; net profit attributable to the parent company was 101 million yuan, a year-on-year decrease of 64.70%. After deducting non-recurring gains and losses, the net profit was 165 million yuan, a year-on-year decrease of 38.29%. The basic earnings per share were 0.05 yuan, and it is proposed to distribute a cash dividend of 0.30 yuan for every 10 shares. The decline in net profit was mainly due to a decrease in revenue from the pharmaceutical distribution and medical services sectors, a decline in gross profit margin, and an increase in non-recurring gains and losses